GSK, one of the top pharmaceutical companies, is facing new delays over the approval of their vaccine Cervarix that is aimed for the treatment of cervical cancers. GSK said that the reason for delay is because the FDA failed to complete their review on Cervarix by the anticipated deadline. However, soon GSK was dragged into deeper problems when a 14-year old school girl in UK died hours after receiving the Cervarix vaccine.

However, the FDA has clearly denied that the cause for the delay was not because of the death. Hours later, NHS declared that the post-mortem was done and they are assured that the death was not due to the vaccine. GSK says that they are confident about Cervarix and will submit their reports to FDA and are expecting that

...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

DrStockPick.com Watch List!

My Picks for Wednesday September 16, 2009, are:

**************************************************************

MVIS, Microvision, Inc.

MVIS is a global leader in innovative ultra-miniature projection display and image capture products for mobility applications

Today was the commercial introduction of the world’s first laser-based pico projector, called SHOW WX™, based on its proprietary PicoP® display engine technology.

The MVIS pico projector uses the revolutionary laser-based PicoP display engine that delivers large, colorful, bright, and vivid images that are always in focus, regardless of projection distance. The accessory product is a simple plug-n-play pico projector for people on-the-go who

...

HGSI’s Benlysta meets its endpoints in Bliss-52 phase III trial for lupus Earlier today, Human Genome Sciences, Inc. (HGSI) and GlaxoSmithKline PLC (GSK) announced that Benlysta met the primary endpoint in BLISS-52, the first of two pivotal phase III trials in patients with serologically active systemic lupus erythematosus (SLE). In the placebo-controlled BLISS-52 study, the results showed that Benlysta plus standard of care achieved a clinically and statistically significant improvement in patient response rate at Week 52 compared with standard of care alone. Study results also showed that Benlysta was generally well tolerated, with adverse event rates comparable between belimumab and placebo treatment groups. As a reminder, HGSI and GSK is co-developing Benlysta as a potential treatment for SLE. Benlysta is a human monoclonal antibody that specifically recognizes and inhibits the biological activity of B-lymphocyte stimulator (BLyS). BLyS is a naturally occurring protein discovered ...

div style="text-align: justify;"Credit Suisse notesspan style="font-weight: bold;" Roche and GSK/span could see an EPS benefit of ca 0.5% for every incrementalbr /$200M of flu related sales. Roche/Chugai/Gilead are the most likely to benefit (through increased Tamiflu sales) although GSK may also gain (through increased Relenza sales). In the longer-term, companies with pandemic flu vaccine know how may be able to develop a pandemic vaccine, and we may also see an increase in overall influenza vaccines. The main pandemic and seasonal manufacturers are GSK, Sanofi- Aventis and Novartis.br /br /span style="font-weight: bold;"Mexico is in the midst of a flu outbreak which is believed to be due to a novel strain of swine flu (H1N1). /spanSwine flu is typically not transmissible from human to human but in this case appears to have become transmissible. Given its novelty compared to prior influenza viruses in humans, it appears to be relatively more severe than ...